South Korean firm formally launches buyout of Trimeris
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
DURHAM, N.C. – South Korea-based Arigene launched its buyout of Trimeris (Nasdaq: TRMS) Monday morning with an offer of $3.60 per share.
Trimeris shares closed at $3.46 on Friday.
The company developed the HIV drug Fuzeon, which is manufactured and sold internationally by Roche.
Arigene is making the buy through its subsidiary RTM Acquisition Company. Arigence announced plans to buy Trimeris for some $81 million on Oct. 2.
The offer is in cash.
Once the deal is closed, RTM and Trimeris will be merged with Trimeris operating as a subsidiary of Arigene.
“Acquisition of Trimeris would represent Arigene’s first step towards the launch of a research and development center in Korea to act as a facilitator to private ventures, governments and educational institutions within the biotechnology industry,” Arigene said in a statement.
The boards of both firms have already approved the deal.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Groundwork Labs refocuses mission as Triangle Startup Factory nears launch
- Epic Games' Tim Sweeney reaps arts Hall of Fame honor today
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says